Press Release


Teknova Reports Third Quarter 2021 Financial Results

November 10, 2021 at 4:01 PM EST

$9.4 million in total revenue, up 5% year-over-year
Excluding Sample Transport, total revenue was $9.3 million, up 26% year-over-year
Strong cash position of $98.0 million supports investment in long-term growth strategy

HOLLISTER, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical products, including drug therapies, novel vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2021.

“Teknova performed very well during the third quarter of 2021. We met robust customer demand for our Lab Essentials and Clinical Solutions products and made meaningful progress in advancing our strategic priorities, including investing in our manufacturing capacity and successfully recruiting priority leadership hires,” said Stephen Gunstream, President and CEO of Teknova. “We remain focused on both near-term execution and the laying of the foundation for our long-term growth opportunities.”

Corporate and Financial Updates

  • Achieved third quarter 2021 revenue of $9.4 million, up 5% as compared to $9.0 million in the third quarter 2020 and up 26% as compared to $7.4 million in the third quarter 2020, when Sample Transport is excluded
  • Invested in manufacturing capacity expansion in existing facilities and construction of a new, state-of-the art GMP manufacturing facility in Hollister, California, including new hires with process development and automation expertise
  • Expanded the Company’s leadership team in November by appointing two key commercial roles, Ken Gelhaus as Chief Commercial Officer and Jennifer Henry as SVP, Marketing

Revenue for the Third Quarter and Year-to-Date

$000sThree months ended
Nine months ended
 September 30, 2021September 30, 2021
Unaudited20212020Inc/Dec 20212020Inc/Dec 
Lab Essentials7,1955,81524%20,44015,49432%
Clinical Solutions1,6901,35425%4,3543,14139%
Sample Transport731,593(95%)1,0351,767(41%)
Total Revenue9,3928,9845%26,78321,14027%

Third Quarter 2021 Financial Highlights

Total revenues for the third quarter 2021 were $9.4 million, a 5% increase from $9.0 million in the third quarter 2020. Excluding Sample Transport, revenues for the third quarter 2021 were $9.3 million, a 26% increase from $7.4 million in the third quarter 2020.

Gross profit for the third quarter 2021 was $4.3 million, compared to $5.1 million in the third quarter 2020. Gross margin for the third quarter 2021 was 45.4% of revenue, compared to 56.6% of revenue in the third quarter 2020. The Company continued to make investments in manufacturing capacity and related infrastructure in anticipation of increases in future demand, which negatively impacted gross margins in 2021.

Operating expenses for the third quarter 2021 were $8.2 million, compared to $2.9 million in the third quarter 2020. The increase was driven by new hires in the research and development, sales and marketing, and general and administrative functions needed to support new product development efforts, develop commercial presence and improve customer support, and to build the infrastructure necessary to support the Company’s growth strategy.

Net loss attributable to common stockholders for the third quarter 2021 was $3.3 million, or $0.12 per share, compared to net income attributable to common stockholders of $0.3 million, or $0.07 per share, for the third quarter 2020.

Adjusted EBITDA for the third quarter 2021 was negative $2.7 million, compared to positive $2.7 million for the third quarter 2020. Adjusted Free Cash Flow was negative $6.6 million in the third quarter 2021, compared to positive $1.7 million the third quarter 2020, reflecting continued capital investment in manufacturing operations.

As of September 30, 2021, the Company had $98.0 million in cash and cash equivalents.

Conference Call and Webcast

Teknova will host a webcast and conference call today, Wednesday, November 10, 2021, beginning at 4:30 p.m. ET. Participants may access the live webcast on the Investor Relations section of the Teknova website,, and at this link: The conference call can be accessed by dialing 877-312-1451 for domestic callers and 470-495-9521 for international callers. The conference ID number is 5889934. A replay will be available for 30 days on the Investor Relations section of the Teknova website.

About Teknova

Teknova is expediting clinical breakthroughs in the life sciences by providing custom products and reagents for bioprocessing, bioproduction, and molecular diagnostics. With a focus on agility and customization, Teknova delivers research-grade and GMP products, including cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents for a multitude of established and emerging applications, including cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology. Teknova's proprietary processes enable the manufacture and delivery of high quality, custom, made-to-order products on short turnaround times and at scale across all stages of development, including commercialization.

Non-GAAP Financial Measures

This press release contains financial measures that have not been calculated in accordance with U.S. generally accepted accounting principles (GAAP). Teknova uses the following non-GAAP financial measures in assessing the performance of our business and the effectiveness of our business strategies: (a) Adjusted EBITDA and (b) Adjusted Free Cash Flow.

Teknova defines Adjusted EBITDA as net income (loss) adjusted for interest expense, provision for income taxes, depreciation expense, amortization of intangible assets, and stock-based compensation expense. Adjusted EBITDA reflects further adjustments to eliminate the impact of certain items, including certain non-cash and other items that we do not consider representative of our ongoing operating performance.

Teknova defines Adjusted Free Cash Flow as Adjusted EBITDA less capital expenditures.

Teknova presents Adjusted EBITDA and Adjusted Free Cash Flow in this press release because Teknova believes analysts, investors, and other interested parties frequently use these measures to evaluate companies in our industry and that such measures facilitate comparisons on a consistent basis across reporting periods. Further, Teknova believes such measures are helpful in highlighting trends in our operating results because they exclude items that are not indicative of our core operating performance.

Adjusted EBITDA and Adjusted Free Cash Flow have limitations as analytical tools and you should not consider them in isolation or as substitutes for analysis of our results as reported under GAAP. Teknova may in the future incur expenses similar to the adjustments in the presentation of Adjusted EBITDA. In particular, Teknova expects to incur meaningful share-based compensation expense in the future. Other limitations include the following, which Adjusted EBITDA and Adjusted Free Cash Flow do not reflect:

  • all expenditures or future requirements for capital expenditures or contractual commitments;
  • changes in our working capital needs;
  • provision for income taxes, which may be a necessary element of our costs and ability to operate;
  • the costs of replacing the assets being depreciated, which will often have to be replaced in the future;
  • the non-cash component of employee compensation expense; and
  • the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations.

In addition, Adjusted EBITDA and Adjusted Free Cash Flow may not be comparable to similarly titled measures used by other companies in our industry or across different industries.

A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to our long-term growth strategy, demand for our products, expansion of our production capacity and commercial and R&D capabilities. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. These forward-looking statements are based on management’s current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, those related to our cash flows and revenue growth rate; our supply chain, sourcing, manufacturing and warehousing; inventory management; risks related to global economic and marketplace uncertainties related to the impact of the COVID-19 pandemic; reliance on a limited number of customers for a high percentage of our revenue; acquisitions of other companies and other factors discussed in the “Risk Factors” section of our most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including in our final prospectus filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended, on June 25, 2021, all of which you may obtain for free on the SEC’s website at Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Condensed Balance Sheets
(In thousands)

 As of As of
 September 30, 2021 December 31, 2020
Current assets:    
Cash and cash equivalents$98,013  $3,315 
Short-term investments – marketable securities    1,811 
Accounts receivable, net 4,558   4,623 
Inventories, net 4,403   3,582 
Income taxes receivable 1,191   1,417 
Prepaid expenses and other current assets 2,914   1,666 
Total current assets 111,079   16,414 
Property, plant and equipment, net 22,451   10,008 
Goodwill 16,613   16,613 
Intangible assets, net 18,991   19,852 
Other non-current assets 29   24 
Total assets$169,163  $62,911 
Current liabilities:    
Accounts payable$3,321  $1,635 
Accrued liabilities 2,883   2,327 
Total current liabilities 6,204   3,962 
Deferred tax liabilities 4,350   5,990 
Other accrued liabilities 293   350 
Long-term debt 11,826    
Deferred rent 264   204 
Total liabilities 22,937   10,506 
Convertible and redeemable preferred stock    35,638 
Stockholders’ equity:    
Common stock     
Additional paid-in capital 150,117   14,495 
(Accumulated deficit) retained earnings (3,891)  2,265 
Accumulated other comprehensive income    7 
Total stockholders’ equity 146,226   16,767 
Total liabilities, convertible and redeemable preferred stock and stockholders’ equity$169,163  $62,911 

Condensed Statements of Operations
(In thousands, except share and per share data)

 For the Three Months For the Nine Months
 Ended September 30, Ended September 30,
 2021 2020 2021 2020
Revenue$9,392  $8,984  $26,783  $21,140 
Cost of sales 5,129   3,896   14,141   8,954 
Gross profit 4,263   5,088   12,642   12,186 
Operating expenses:       
Research and development 1,372   358   2,922   1,025 
Sales and marketing 885   558   2,494   1,389 
General and administrative 5,607   1,733   13,606   5,043 
Amortization of intangible assets 287   287   861   861 
Total operating expenses 8,151   2,936   19,883   8,318 
(Loss) income from operations (3,888)  2,152   (7,241)  3,868 
Other income (expenses), net       
Interest income (expense), net (255)  19   (553)  74 
Other expense, net    (2)  (2)  (27)
Total other income (expenses), net (255)  17   (555)  47 
(Loss) income before income taxes (4,143)  2,169   (7,796)  3,915 
(Benefit from) provision for income taxes (892)  636   (1,640)  922 
Net (loss) income (3,251)  1,533   (6,156)  2,993 
Less: undistributed income attributable to preferred stockholders    (1,271)     (2,482)
Net (loss) income attributable to common stockholders$(3,251) $262  $(6,156) $511 
Net (loss) income per share attributable to common stockholders       
Basic$(0.12) $0.07  $(0.51) $0.14 
Diluted$(0.12) $0.07  $(0.51) $0.14 
Weighted average shares used in computing net (loss) income per share attributable to common stockholders       
Basic28,011,917  3,599,232  12,069,214  3,599,232 
Diluted28,011,917  3,647,675  12,069,214  3,632,321 

Condensed Statements of Cash Flows
(In thousands)

 Nine months ended September 30,
 2021 2020
Operating activities:     
Net (loss) income$(6,156) $2,993 
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:     
Bad debt expense 235   (5)
Depreciation and amortization 2,100   1,473 
Stock-based compensation 927   31 
Inventory reserve 676   10 
Deferred taxes (1,640)  1,901 
Amortization of debt issuance costs 89    
Loss on disposal of property, plant and equipment 4   11 
Other (10)  34 
Changes in operating assets and liabilities:     
Accounts receivable (170)  (2,471)
Inventories (1,497)  (360)
Prepaid expenses and other assets (1,569)  (1,923)
Accounts payable, accrued liabilities, and other current and non-current liabilities 964   (1,650)
Deferred rent 60   27 
Cash (used in) provided by operating activities (5,987)  71 
Investing activities:     
Purchase of property, plant and equipment (12,465)  (1,969)
Proceeds from loan to related party 529   20 
Purchase of short-term marketable securities    (1,775)
Proceeds from sales of short-term marketable securities 1,132   1,747 
Proceeds from maturities of short-term marketable securities 695   2,900 
Cash (used in) provided by investing activities (10,109)  923 
Financing activities:     
Proceeds from long-term debt, net 11,890    
Debt issuance costs (153)   
Repayment of long-term debt    (45)
Indemnity holdback release    (1,554)
Payment of issuance costs for initial public offering (3,615)   
Proceeds from initial public offering, net of underwriters’ commissions and discounts 102,672    
Cash provided by (used in) financing activities 110,794   (1,599)
Change in cash and cash equivalents 94,698   (605)
Cash and cash equivalents at beginning of period 3,315   4,144 
Cash and cash equivalents at end of period$98,013  $3,539 

Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures
(In thousands)

 For the Three Months For the Nine Months
 Ended September 30, Ended September 30,
 2021 2020 2021 2020
Net (loss) income – as reported$(3,251) $1,533  $(6,156) $2,993 
Add back:       
Interest (expense) income, net (255)  19   (553)  74 
(Benefit from) provision for income taxes (892)  636   (1,640)  922 
Depreciation expense 461   254   1,239   612 
Amortization of intangible assets 287   287   861   861 
EBITDA$(3,140) $2,691  $(5,143) $5,314 
Other and one-time expenses:       
Stock-based compensation expense 442   31   927   31 
Adjusted EBITDA$(2,698) $2,722  $(4,216) $5,345 
Less: capital expenditures (3,907)  (1,016)  (12,465)  (1,969)
Adjusted Free Cash Flow$(6,605) $1,706  $(16,681) $3,376 
Add back: capital expenditures 3,907   1,016   12,465   1,969 
Less: total other and one time expenses (442)  (31)  (927)  (31)
Less: total interest, taxes, depreciation and amortization               
Expenses (111)  (1,158)  (1,013)  (2,321)
Net (loss) income – as reported$(3,251) $1,533  $(6,156) $2,993 
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities, net 321   1,101   2,381   3,455 
Changes in operating assets and liabilities, net (1,907)  (4,259)  (2,212)  (6,377)
Cash (used in) provided by operating activities$(4,837) $(1,625) $(5,987) $71 

Investor Contacts Matt Lowell Chief Financial Officer +1 831-216-1830 Sara Michelmore MacDougall Advisors +1 781-235-3060 Media Contact Matthew Corcoran MacDougall Advisors +1 617-866-7350